Document Detail


Cytosine arabinoside in the management of recurrent leukaemia.
MedLine Citation:
PMID:  3471699     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A Phase II study of high dose cytosine arabinoside (ara-C) with different schedules in patients with recurrent acute myelogenous leukaemia (AML) and myeloid blast crisis of chronic myeloid leukaemia has been conducted at St. Bartholomew's Hospital. Ara-C was infused continuously for seven days at a dose of 100-200 mgs/m2 daily from day 1 with 1-2 g/m2 (3 h infusions) twice daily from day 2 for six days. Nineteen patients with acute myelogenous leukaemia and four patients with myeloid blast crisis of chronic myeloid leukaemia (CML) were treated. Complete remission was achieved in 4/19 patients with AML and in a further four patients an antileukaemic effect was observed. There were eight early deaths and three patients failed to show any response to therapy. All four patients with myeloid blast crisis of CML failed to respond to the treatment. Toxicity was considerable with gastro-intestinal and hepatotoxicity being the most serious problems. Pharmacokinetic studies revealed that mean basal levels achieved with continuous infusion prior to high-dose ara-C were 10(2) ng/ml and peak levels were of the order of 10(4) ng/ml. The considerable toxicity of the regimen, without clinical advantage over less intensive programmes, resulted in its termination.
Authors:
T S Ganesan; M J Barnett; R J Amos; E M Piall; G W Aherne; A Man; T A Lister
Related Documents :
6831459 - Evaluation of the immunological and toxicological properties of mve-2 in phase i trials.
20222909 - Ribavirin dosage in patients with hcv genotypes 2 and 3 who completed short therapy wit...
6176159 - Recombinant leukocyte a interferon: pharmacokinetics, single-dose tolerance, and biolog...
16507779 - Activity of subcutaneous interleukin-12 in aids-related kaposi sarcoma.
21282909 - [usefulness and safety of propranolol injection into vein for acquisition of coronary m...
2205379 - Phase i trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer ...
25056789 - How does airway exposure of aflatoxin b1 affect serum albumin adduct concentrations? ev...
16354399 - Size-dependent disposition of nanoparticles and microparticles following subconjunctiva...
7759769 - Effects of ethinylestradiol on the course of spontaneous autoimmune disease in nzb/w an...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Hematological oncology     Volume:  5     ISSN:  0278-0232     ISO Abbreviation:  Hematol Oncol     Publication Date:    1987 Jan-Mar
Date Detail:
Created Date:  1987-05-29     Completed Date:  1987-05-29     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8307268     Medline TA:  Hematol Oncol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  65-9     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Blast Crisis / drug therapy*
Cytarabine / adverse effects,  therapeutic use*
Drug Evaluation
Humans
Leukemia, Myeloid / drug therapy,  pathology*
Leukemia, Myeloid, Acute / drug therapy*
Chemical
Reg. No./Substance:
147-94-4/Cytarabine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The effects of a constant T3 level and thermoneutrality in diet-induced hyperphagia.
Next Document:  A new translocation t(1;4;11) in congenital acute nonlymphocytic leukemia (acute myeloblastic leukem...